Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CT-868

A Study of CT-868 in Type 1 Diabetes Mellitus

Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 111

NCT06062069

ArmPopulationDoseWeeksEstimandWeight change
CT-868 Low DoseObesity + T2Dn/r16n/rn/r
CT-868 Medium DoseObesity + T2Dn/r16n/rn/r
CT-868 High DoseObesity + T2Dn/r16n/rn/r
CT-868 PlaceboObesity + T2Dn/r16n/rn/r
Arm 2: CT-868 Titrated to 1.8 mgObesity + T2D1.8 mg16n/rn/r
Arm 3: CT-868 Titrated to 4.1 mgObesity + T2D4.1 mg16n/rn/r
Arm 4: CT-868 Titrated to 6.6 mgObesity + T2D6.6 mg16n/rn/r